London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.

IntroductionThe demand for ENT (Ears, Nose, and Throat) treatment solutions is rising significantly due to the increasing ...

CTB-201 is under development for the treatment of chronic sinusitis. It is administered as intranasal spray. It is a preparation of recombinant human CC10 protein (rhCC10). CC10 was the most abundant ...

Sinusitis is a condition that occurs when sinuses become inflamed due to infections Read this article to know what might be ...

A cough can be irritating at any time of day or night. It disrupts your daily routine and the precious hours of sleep you get ...

The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with ...

Chronic migraine becomes “refractory” when preventive treatments don’t work to reduce the frequency of episodes. Treatment may include complementary therapies like neuromodulation.